New 52 Week Low Today

Galapagos NV GLPG:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EST
37.44UNCH (UNCH)
Volume
231
Close
37.44quote price arrow down-0.39 (-1.03%)
Volume
275,358
52 week range
37.24 - 72.11
Loading...
  • Open37.40
  • Day High37.72
  • Day Low37.24
  • Prev Close37.83
  • 52 Week High72.11
  • 52 Week High Date04/07/22
  • 52 Week Low37.24
  • 52 Week Low Date12/09/22

Key Stats

  • Market Cap2,663.05M
  • Shares Out65.84M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta0.07
  • YTD % Change-32.09

KEY STATS

  • Open37.40
  • Day High37.72
  • Day Low37.24
  • Prev Close37.83
  • 52 Week High72.11
  • 52 Week High Date04/07/22
  • 52 Week Low37.24
  • 52 Week Low Date12/09/22
  • Market Cap2,663.05M
  • Shares Out65.84M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta0.07
  • YTD % Change-32.09

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date02/23/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Galapagos NV

 

Profile

MORE
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It...
Paulus Stoffels
Chairman of the Board, Chief Executive Officer
Bart Filius
President, Chief Financial Officer, Chief Operating Officer, Member of the Management Board
Address
Generaal De Wittelaan L11 A3
Malines (mechelen)
2800
Belgium

Top Peers